Multiple Myeloma | Specialty

Immunotherapy Is on the Cusp of Major Breakthroughs in Multiple Myeloma

March 1st 2021

Immune therapy has evolved rapidly in multiple myeloma, and the field is on the verge of major improvements in outcomes.

FDA Approves Melphalan Flufenamide for Relapsed/Refractory Multiple Myeloma

February 27th 2021

The FDA has approved melphalan flufenamide for use in combination with dexamethasone in the treatment of select adult patients with relapsed/refractory multiple myeloma.

Dr. Dhakal on the Mechanism of Action of Orva-Cel in Multiple Myeloma

February 26th 2021

Binod Dhakal, MD, discusses the mechanism of action of orvacabtagene autoleucel in multiple myeloma.

Bispecific Antibodies Propel the Relapsed/Refractory Myeloma Paradigm Further Ahead

February 25th 2021

Timothy M. Schmidt, MD, discusses the integration and utility of bispecific antibodies in relapsed/refractory multiple myeloma, as well as some of the most promising agents in clinical development.

Emerging Novel Agents in RRMM

February 25th 2021

Paul G. Richardson, MD, reviews early data presented at ASH 2020 on the use of CELMoDs as well as melflufen for the management of RRMM. 

Using PI-based Combinations in RRMM

February 25th 2021

Saad Z. Usmani, MD, leads the discussion on new and updated data for novel PI-based combinations in RRMM as seen in the CANDOR, IKEMA, and BOSTON trials.

ADCs, Triplets, and Transplant Maintain Solid Roles in Multiple Myeloma Therapy

February 24th 2021

Natalie S. Callander, MD, discusses the intriguing approaches in both the frontline and relapsed/refractory settings, including trials with antibody-drug conjugates.

CAR T-Cell Therapy Explodes on the Scene in Heavily Pretreated Multiple Myeloma

February 24th 2021

Binod Dhakal, MD, discusses the potential impact of ide-cel, orva-cel, and cilta-cel in multiple myeloma therapy.

Dr. Nooka on the Utility of BCMA as a Target in Multiple Myeloma

February 23rd 2021

Ajay K. Nooka, MD, MPH, FACP, discusses the utility of BCMA as a target in multiple myeloma.

Dr. Schmidt on the Safety and Efficacy of Teclistamab in Multiple Myeloma

February 22nd 2021

Timothy M. Schmidt, MD, discusses the safety and efficacy of teclistamab in patients with multiple myeloma.

Dr. Callander on the Potential Future of Belantamab Mafodotin in Multiple Myeloma

February 19th 2021

Natalie S. Callander, MD, discusses the potential future of belantamab mafodotin-blmf in multiple myeloma.

Novel Additions Require Nuanced Treatment Selection in Relapsed/Refractory Myeloma

February 19th 2021

Parameswaran Hari, MD, MRCP, discusses single-agent and combination strategies that have recently been introduced to the relapsed/refractory multiple myeloma setting and the nuances to utilizing them in clinical practice.

CAR T-Cell Therapy Carves Out a Role in Multiple Myeloma

February 18th 2021

Yi Lin, MD, PhD, discusses promising data with CAR T-cell therapy in multiple myeloma.

Using MRD to Inform Treatment Decisions in Transplant-Eligible Myeloma

February 18th 2021

Rafael Fonseca, MD, discusses several clinical trials that support the use of quadruplet regimens in myeloma, the utilization of MRD in clinical decision-making, and future directions for research.

Role of IMiD-based Strategies for RRMM

February 18th 2021

Approaching Treatment of RRMM

February 18th 2021

Looking to Novel Immunotherapeutics in Relapsed/Refractory Multiple Myeloma

February 17th 2021

Marc J. Braunstein, MD, PhD, discusses the evolution and promise of immunotherapeutics in multiple myeloma.

Dr. Hari on the Role of Carfilzomib, Pomalidomide, and Dexamethasone in R/R Myeloma

February 17th 2021

Parameswaran Hari, MD, MRCP, discusses the efficacy of combination carfilzomib, pomalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma.

Dr. Hari on Mitigating Selinexor-Related Toxicities in Multiple Myeloma

February 16th 2021

Parameswaran Hari, MD, MRCP, discusses mitigating selinexor-related toxicities in relapsed/refractory multiple myeloma.

Dr. Dhakal on Responses Achieved With Orva-Cel in Multiple Myeloma

February 16th 2021

Binod Dhakal, MD, discusses responses achieved with orvacabtagene autoleucel in patients with multiple myeloma.